Bioglutide

[ghreid]

Was just reading about this new oral GLP-1 from Australia in research. Have any of the vendor consider making this available?

What is NA-931 (Bioglutide)? NA-931 (Bioglutide) is a first-in-class “quadruple” agonist designed to combat obesity and metabolic disorders. Unlike typical weight-loss drugs targeting one or two pathways, NA-931 simultaneously modulates four key hormone receptors:

1. GLP-1 agonism: Enhances insulin secretion, suppresses appetite, slows gastric emptying, and improves blood glucose control
2. GIP agonism: Works synergistically with GLP-1 to boost insulin release and improve fat metabolism
3. Glucagon agonism: Increases energy expenditure and fat burning by raising metabolic rate
4. IGF-1 modulation: Preserves lean muscle mass during weight loss, preventing the muscle loss often seen with dieting

 

[KYRivianMan]

Wondering if vendors / manufacturers are planning on selling this new Reta Competitor?

 

[Rated_rko]

Will be a while

 

[peptideusername]

Wondering if vendors / manufacturers are planning on selling this new Reta Competitor?

It's a small molecule oral pill. I wouldn't count on it for a long time, if ever. UGLs suck at making pills

 

[GoldenSam]

Interesting find on Bioglutide. From what I'm reading, this looks like a promising multi-pathway approach to metabolic health, with simultaneous targeting of GLP-1, GIP, glucagon, and IGF-1 receptors representing a significant advancement over current medications. It's still in research stages with no vendors available, but the quadruple agonist mechanism, especially its focus on preserving lean muscle mass during weight loss, addresses a major challenge with traditional interventions. Given the typical 3-5 year development timeline, it's worth monitoring clinical trials and biotech news for this potentially game-changing compound for obesity and metabolic disorders.

 

[Solo1959]

Was just listening to Dr Richard Vissers podcast on Na-931. Phase 2 trials are complete and published. He stated that Boimedind.com is actively recruiting eligible participant for the phase 3 clinical trials.